Repros Therapeutics

Repros Therapeutics — Zonagen — Investor Presentation (April 2005)

28 slides from Repros Therapeutics's investor presentation, Apr 26, 2005

  1. Slide 1: We develop advanced endocrine therapeutics

    We develop advanced endocrine therapeutics to treat patients with hormonal and reproductive system disorders.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements and information regarding the future performance and actions of Zonagen that involve risks and uncertainties that could cause actual results and actions to differ materially. These risks include those discussed in this

  3. Slide 3: Zonagen Investment Highlights

    Zonagen Investment Highlights Focused on Large, Poorly-served Markets Uterine fibroids - +/- 80% US women (1 in 4 severe) - no current drug cure Endometriosis - 5.5 million US and Canadian women Testosterone deficiency - 13 million US men Multiple Value-driving Milestones - Two potential pivotal tri

  4. Slide 4: Zonagen Overview

    Zonagen Overview Successful restart in 2004 Current Zonagen Portfolio: 2 Phase II hormonal antagonists ProgentaTM (antiprogestin) - multiple indications Completed 30 patient Phase Ib European trial Existing leading therapy causes significant bone loss AndroxalTM (antiestrogen) Completed 52 patient P

  5. Slide 5: Zonagen Strategy

    Zonagen Strategy Focus on small molecule programs for reproductive system disorders Outsource activities relating to clinical trials Opportunistic in-licensing of small molecule programs targeting our niche expertise at pre- clinical stage Out-licensing of Company programs at end of large Phase II s

  6. Slide 6: Progenta

    ProgentaTM Uterine Fibroids - 80% US women - - Phase II/III 2H 05 Endometriosis - 5.5 million US/Canadian women - - Phase II 2H 05

  7. Slide 7: Progenta Overview

    ProgentaTM Overview New class of selective progesterone receptor modulator (SPRM) Potential indications: uterine fibroids, endometriosis, breast cancer and HRT Potential significant advantages over existing GnRHa therapies No loss of bone mineral density in clinical trials No chronic drug treatment

  8. Slide 8: How Progenta Works

    How ProgentaTM Works Hypothalamus Pituitary Endometrial & Uterine Tissue GnRHa Block hypothalamus / pituitary axis Shuts down hormonal secretions Long-term side effects including bone loss ProgentaTM Selectively block progesterone activity Allow tonic hormone secretions Provide symptomatic relief Sh

  9. Slide 9: Market & Competition

    Market & Competition Uterine Fibroids Up to 80% of women 25% have symptoms requiring treatment Most frequent indication for hysterectomy Account for 40% of total $1-$1.5 billion spent annually in U.S. No current drug cure GnRH agonists (Lupron(r)) most effective drug therapy Bone loss and fibroid re

  10. Slide 10: Phase Ib Uterine Fibroid Trial

    Phase Ib Uterine Fibroid Trial Design: N=30 Women with signs and symptoms of uterine fibroids Doses of 0, 12.5, 25, 50 mg Progenta TM and Lupron(r) Placebo and ProgentaTM arms blinded; Lupron(r) open-label Treated for 1 month with potential for 2 month extension 3 European referral sites, one clinic

  11. Slide 11: Initial Progenta Results

    Initial ProgentaTM Results 4 weeks 8 weeks 12 weeks 12.5 mg Progenta 99.4 70.4 83.3 25 mg Progenta 101.3 76 64.9 50 mg Progenta 72.7 67.5 59.1 Lupron 81.5 62.1 62.5 Placebo 82.6 102.8 95 Uterine Fibroid Study

  12. Slide 12: Fibroid Regulatory Strategy

    Fibroid Regulatory Strategy Conduct pre-IND meeting 1H05 Develop drug initially as pre-operative therapy pending pre-IND meeting (May 20, 2005) Potentially more rapid development Extend studies for chronic indication Pursue initiation of U.S. Phase II/III uterine fibroid study under SPA

  13. Slide 13: Proposed Phase II Endometriosis Trial

    Proposed Phase II Endometriosis Trial H2-2005 Design N=40 Women with endometriosis Treated for 6 months with same doses as fibroid study Active control: GnRHa (Lupron(r)) Endpoints Pain Lesion Size by MRI Bone Loss Markers Regulatory Strategy Evaluate data from European Phase II before commencing U.

  14. Slide 14: Progenta Milestones

    ProgentaTM Milestones 1H05 Conduct Pre-IND meeting with FDA 1H05 Complete European Phase Ib data analysis 2H05 Commence European endometriosis Phase II study 2H05 Secure SPA for fibroids 2H05 Commence U.S. fibroid Phase II/III study 1H06 Report Top Line Phase II endometriosis results 1H06 Report Top

  15. Slide 15: Androxal

    AndroxalTM Completed 52 patient Phase II US trial Data suggests safe and effective orally administered therapy for hypogonadism

  16. Slide 16: Androxal Overview

    AndroxalTM Overview Oral, central-acting antagonist, induces testosterone production Indication: Restoration of normal testosterone levels Advantages over existing therapies Superior efficacy data in clinical trials - US Phase I/II Oral non-testosterone therapy Capable of replicating normal circadia

  17. Slide 17: How Androxal Works

    How AndroxalTM Works Hypothalamus Pituitary Axis Testes Estrogen Androxal LH Surge Increased Testosterone Secretion

  18. Slide 18: Testosterone Replacement Market

    Gels Transdermal Orals Injectibles Testosterone Replacement Market 71.5 14.5 2.4 11.6 Testosterone Replacement Market 2003 = $375 million market opportunity Source: IMS Health

  19. Slide 19: Androxal Phase II Trial

    AndroxalTM Phase II Trial N = 52 men Patient testosterone levels < 300 ng/dl Randomized into 5 arms 3 doses of AndroxalTM Placebo Low doses of Androgel(r) 6th arm conducted among 10 men previously enrolled at high dose of Androgel(r) Placebo and AndroxalTM doses were double-blinded Androgel(r) admin

  20. Slide 20: Final Results

    Final Results 12.5 mg 169 25 mg 247 50 mg 294 Androgel 5g 212 Androgel 10g 362 Placebo -1 Effects on Total Testosterone Phase II Trial - final data P=0.0053 P=0.0002 P=0.0005 P=0.019 P=0.043

  21. Slide 21: Androxal Regulatory Strategy

    AndroxalTM Regulatory Strategy Seek approval for the treatment of secondary hypogonadism Estimated 13 million men in US with low testosterone Seek Special Protocol Assessment (SPA) from FDA for conduct of Phase III studies Conduct at least one Phase III trial in the U.S.

  22. Slide 22: Androxal Milestones

    AndroxalTM Milestones 2H05 Obtain SPA for Phase III trials 1H06 Report Initial Phase III results 2006 Conduct second pivotal trial 2008 Submit NDA

  23. Slide 23: Management and Financials

    Management and Financials

  24. Slide 24: Scientific Advisory Boards

    Scientific Advisory Boards AndroxalTM Ronald Swerdloff, M.D., UCLA Chief, Division of Endocrinology, Metabolism, and Nutrition Harbor-UCLA Medical Center Jean Fourcroy, M.D. Past President of the American Medical Women's Association Recipient of a 1998 American Urological Association Presidential Ci

  25. Slide 25: Zonagen Management/Board

    Zonagen Management/Board Joseph Podolski, President/CEO 34 years drug development experience Louis Ploth, CFO, VP Business Development 18 years biotech financial and business development experience Jean Fourcroy M.D. Ph.D. Extensive FDA, regulatory and clinical experience Daniel Cain 26 years experi

  26. Slide 26: Zonagen Financial Data

    Zonagen Financial Data 2004 2003 2002 Income Statement Income Statement Revenues $257 $1,015 $5,254 Expenses Research and Development 2,471 2,161 6,420 General and Administrative 1,483 2,183 2,716 Net Loss ($3,697) ($3,329) ($3,882) Per Share ($0.72) ($0.29) ($0.34) Shares Out 5,117 11,487 11,412 Ba

  27. Slide 27: Zonagen Investment Highlights

    Zonagen Investment Highlights Focused on Large, Poorly-served Markets Uterine fibroids - +/- 80% US women (1 in 4 severe) - no current drug cure Endometriosis - 5.5 million US and Canadian women Testosterone deficiency - 13 million US men Multiple Value-driving Milestones - Two potential pivotal tri

  28. Slide 28: We develop advanced endocrine therapeutics

    We develop advanced endocrine therapeutics to treat patients with hormonal and reproductive system disorders.

Zonagen — Investor Presentation (April 2005) on 6ix